Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment
Condition: Immunotherapy Intervention: Drug: olaparib, durvalumab, tremelimumab Sponsors: Centre Georges Francois Leclerc; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cancer | Cancer & Oncology | Gastroschisis Repair | Genetics | Immunotherapy | Research | Study